Aptinyx Stock Forecast, Price & News

-0.19 (-6.13 %)
(As of 06/21/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume1.20 million shs
Average Volume851,205 shs
Market Capitalization$198.39 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive APTX News and Ratings via Email

Sign-up to receive the latest news and ratings for Aptinyx and its competitors with MarketBeat's FREE daily newsletter.

Aptinyx logo

About Aptinyx

Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II clinical trial for treating fibromyalgia. It is also developing NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase I clinical trial to treat post-traumatic stress disorder; and NYX-458, an NMDAr modulator, which is in Phase I clinical study for the treatment of Parkinson's disease cognitive impairment. The company has a research collaboration agreement with Allergan plc. Aptinyx Inc. was incorporated in 2015 and is headquartered in Evanston, Illinois.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.51 out of 5 stars

Medical Sector

570th out of 2,101 stocks

Pharmaceutical Preparations Industry

275th out of 831 stocks

Analyst Opinion: 3.4Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Aptinyx (NASDAQ:APTX) Frequently Asked Questions

Is Aptinyx a buy right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aptinyx in the last year. There are currently 1 sell rating and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Aptinyx stock.
View analyst ratings for Aptinyx
or view top-rated stocks.

What stocks does MarketBeat like better than Aptinyx?

Wall Street analysts have given Aptinyx a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Aptinyx wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Aptinyx's next earnings date?

Aptinyx is scheduled to release its next quarterly earnings announcement on Thursday, August 12th 2021.
View our earnings forecast for Aptinyx

How were Aptinyx's earnings last quarter?

Aptinyx Inc. (NASDAQ:APTX) released its quarterly earnings results on Wednesday, May, 12th. The company reported ($0.22) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.21) by $0.01. The business earned $1 million during the quarter. Aptinyx had a negative trailing twelve-month return on equity of 37.99% and a negative net margin of 2,108.05%.
View Aptinyx's earnings history

How has Aptinyx's stock price been impacted by Coronavirus?

Aptinyx's stock was trading at $2.43 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, APTX shares have increased by 19.3% and is now trading at $2.90.
View which stocks have been most impacted by COVID-19

What price target have analysts set for APTX?

9 analysts have issued 12-month price targets for Aptinyx's shares. Their forecasts range from $8.00 to $15.00. On average, they expect Aptinyx's share price to reach $11.67 in the next twelve months. This suggests a possible upside of 302.3% from the stock's current price.
View analysts' price targets for Aptinyx
or view top-rated stocks among Wall Street analysts.

Who are Aptinyx's key executives?

Aptinyx's management team includes the following people:
  • Dr. Norbert G. Riedel, CEO & Director (Age 63, Pay $826.78k)
  • Dr. Andrew Kidd M.D., B.M. B.Ch., Pres & COO (Age 45, Pay $594.37k)
  • Mr. Ashish Khanna, CFO & Chief Bus. Officer (Age 45, Pay $580.19k)
  • Mr. Juan Estupinan, VP of Fin. & Accounting and Controller
  • Mr. Nicholas C. Smith, Director of Corp. Devel.
  • Dr. Kathryn King, Sr. VP - Clinical Devel.
  • Mr. Harald Murck M.D., Ph.D., VP of Medical & Pharmacovigilance

Who are some of Aptinyx's key competitors?

What other stocks do shareholders of Aptinyx own?

When did Aptinyx IPO?

(APTX) raised $77 million in an initial public offering on Thursday, June 21st 2018. The company issued 5,300,000 shares at $14.00-$15.00 per share. J.P. Morgan, Cowen, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO.

What is Aptinyx's stock symbol?

Aptinyx trades on the NASDAQ under the ticker symbol "APTX."

Who are Aptinyx's major shareholders?

Aptinyx's stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (4.59%), Millennium Management LLC (2.07%), Renaissance Technologies LLC (1.12%), Geode Capital Management LLC (0.89%), Northern Trust Corp (0.68%) and Assenagon Asset Management S.A. (0.63%). Company insiders that own Aptinyx stock include Adam Koppel, Adams Street Partners Llc, Bain Capital Life Sciences Inv, Norbert G Riedel, Rachel E Sherman and Robert J Hombach.
View institutional ownership trends for Aptinyx

Which major investors are selling Aptinyx stock?

APTX stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Morgan Stanley, Renaissance Technologies LLC, JPMorgan Chase & Co., GSA Capital Partners LLP, Assenagon Asset Management S.A., and Goldman Sachs Group Inc..
View insider buying and selling activity for Aptinyx
or view top insider-selling stocks.

Which major investors are buying Aptinyx stock?

APTX stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Geode Capital Management LLC, Northern Trust Corp, Squarepoint Ops LLC, Nuveen Asset Management LLC, Ameriprise Financial Inc., Barclays PLC, and Dimensional Fund Advisors LP. Company insiders that have bought Aptinyx stock in the last two years include Adam Koppel, Adams Street Partners Llc, Bain Capital Life Sciences Inv, Norbert G Riedel, Rachel E Sherman, and Robert J Hombach.
View insider buying and selling activity for Aptinyx
or or view top insider-buying stocks.

How do I buy shares of Aptinyx?

Shares of APTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aptinyx's stock price today?

One share of APTX stock can currently be purchased for approximately $2.90.

How much money does Aptinyx make?

Aptinyx has a market capitalization of $197.70 million and generates $1.56 million in revenue each year. The company earns $-50,050,000.00 in net income (profit) each year or ($1.02) on an earnings per share basis.

How many employees does Aptinyx have?

Aptinyx employs 34 workers across the globe.

What is Aptinyx's official website?

The official website for Aptinyx is

Where are Aptinyx's headquarters?

Aptinyx is headquartered at 909 DAVIS STREET SUITE 600, EVANSTON IL, 60201.

How can I contact Aptinyx?

Aptinyx's mailing address is 909 DAVIS STREET SUITE 600, EVANSTON IL, 60201. The company can be reached via phone at 847-871-0377 or via email at [email protected]

This page was last updated on 6/21/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.